Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Email: | info@poniard.com |
Main Phone: | +1 650 583-3774 |
Address: | 750 Battery Street |
Address 2: | Suite 330 |
State: | CA |
City / Town: | San Francisco |
Country: | USA |
Postal Code: | 94111 |
Exchange: | OTO |
Employees: | 8 |
NAICS: | Pharmaceutical P |
Last Price 0.047 | Change $ 0. | Change % 0.00 | Tick N/A |
Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
Open N/A | High N/A | Low N/A | Prev Close 0.047 |
Last Trade | Volume 55 | 52 Wk Hi 0.18 | 52 Wk Low 0.043 |
Market Cap 70,460 | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
Shares 1,499,159.00 | EPS (TTM) -12.00 | PE Ratio N/A | Exchange OTCPK |
|
|
Last 3 Mo | Last 12 Mo | |
---|---|---|
Number of Insider Trades | 0 | 0 |
Number of Buys | 0 | 0 |
Number of Sells | 0 | 0 |
Net Activity | 0 | 0 |
Last 10 Buys | Shares |
---|---|
Ronald Martell | 1,000 |
Ronald Martell | 1,000 |
Robert Basso | 1,000 |
Frederick Craves | 1,000 |
Frederick Craves | 1,000 |
Frederick Craves | 1,000 |
Frederick Craves | 1,000 |
Frederick Craves | 1,000 |
Frederick Craves | 1,000 |
Frederick Craves | 1,000 |
Last 10 Sell | Shares |
---|---|
Michael Jackson | 1,000 |
Michael Perry | 1,000 |
Michael Jackson | 1,000 |
Michael Jackson | 1,000 |
Michael Jackson | 1,000 |
Nicholas Simon | 1,000 |
Nicholas Simon | 1,000 |
Nicholas Simon | 1,000 |
Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
---|---|---|---|---|
High Target Price Estimate | 10 | 10 | 10 | 2 |
Low Target Price Estimate | 8 | 8 | 8 | 2 |
Mean Target Price Estimate | 9 | 8.67 | 8.67 | 2 |
Standard Deviation | 1.15 | 1.15 | 1.15 | 0 |
Date of Most Recent Estimate | 12/01/08 | 12/12/08 | 12/05/08 | 11/09/10 |
Form Type | Form Description | Pages | Date |
---|---|---|---|
15-12G | Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g). | 1 | 2012-04-02 |
8-K | Report of unscheduled material events or corporate changes. | 4 | 2012-04-02 |
NT 10-K | Notification that form 10-K will be submitted late | 2 | 2012-03-30 |
S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2012-03-29 |
S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2012-03-29 |
S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2012-03-29 |
S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2012-03-29 |
S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2012-03-29 |
S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2012-03-29 |
S-8 POS | Post-effective amendment to an S-8 filing | 3 | 2012-03-29 |
Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 |
Moderate Buy | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 |
Moderate Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 2 |
Mean Rec. | 0 | 0 | 0 | 5 |